| Victor Emmanuel Ylagan, MD | |
|
85 Osborne St, Danbury, CT 06810-6003 | |
| (203) 744-2799 | |
| Not Available |
| Full Name | Victor Emmanuel Ylagan |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 39 Years |
| Location | 85 Osborne St, Danbury, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265464945 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 030512 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Waterbury Hospital | Waterbury, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prospect Ct Medical Foundation Inc | 7416244496 | 267 |
News Archive
Researchers from Nottingham have played their part in the discovery of a rare genetic mutation that increases the risk of Alzheimer's disease, in a study with major implications for understanding the causes of the disease.
Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.
AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the initiation of new strategic alliances with two partners: Novartis and an undisclosed second pharmaceutical company.
Bristol-Myers Squibb Company (NYSE: BMY) and WuXi PharmaTech (NYSE: WX) today announced that they have entered a strategic partnership to conduct stability studies of small-molecule new chemical entities to support global marketing applications.
› Verified 8 days ago
| Entity Name | Prospect Ct Medical Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144677568 PECOS PAC ID: 7416244496 Enrollment ID: O20160919001322 |
News Archive
Researchers from Nottingham have played their part in the discovery of a rare genetic mutation that increases the risk of Alzheimer's disease, in a study with major implications for understanding the causes of the disease.
Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.
AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the initiation of new strategic alliances with two partners: Novartis and an undisclosed second pharmaceutical company.
Bristol-Myers Squibb Company (NYSE: BMY) and WuXi PharmaTech (NYSE: WX) today announced that they have entered a strategic partnership to conduct stability studies of small-molecule new chemical entities to support global marketing applications.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Victor Emmanuel Ylagan, MD 85 Osborne St, Danbury, CT 06810-6003 Ph: (203) 744-2799 | Victor Emmanuel Ylagan, MD 85 Osborne St, Danbury, CT 06810-6003 Ph: (203) 744-2799 |
News Archive
Researchers from Nottingham have played their part in the discovery of a rare genetic mutation that increases the risk of Alzheimer's disease, in a study with major implications for understanding the causes of the disease.
Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.
AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the initiation of new strategic alliances with two partners: Novartis and an undisclosed second pharmaceutical company.
Bristol-Myers Squibb Company (NYSE: BMY) and WuXi PharmaTech (NYSE: WX) today announced that they have entered a strategic partnership to conduct stability studies of small-molecule new chemical entities to support global marketing applications.
› Verified 8 days ago
Tamar Mathias, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 7 Kenosia Ave, Danbury, CT 06810 Phone: 475-329-2686 Fax: 203-456-3161 | |
Dr. Antolin C Trinidad, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 152 West St, Danbury, CT 06810 Phone: 203-791-5140 Fax: 203-798-9200 | |
Mani Sandhya Vemulapalli, M.D Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 24 Hospital Avenue, Danbury Hospital, Danbury, CT 06810 Phone: 203-739-7000 | |
Dr. Peter Gerard Gasparo, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 78 Triangle St, Danbury, CT 06810 Phone: 619-925-5257 | |
Orestes Arcuni, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 24 Hospital Ave, Danbury, CT 06810 Phone: 203-797-7443 | |
Donna Marie Pellerin, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 24 Hospital Ave, Danbury, CT 06810 Phone: 203-797-7443 | |
Dr. Ghazi Asaad, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 72 North Street, Danbury, CT 06810 Phone: 203-748-1200 Fax: 203-790-0010 |